Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. (Q39555847)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961690%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961690%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

main subject

phase I clinical trial

0 references

neurofibromatosis type I

1 reference

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961690%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

9

Baris Turkbey

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961690%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

11

Peter L Choyke

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961690%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

10

Naira Muradyan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961690%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

AeRang Kim

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961690%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Eva Dombi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961690%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Kathleen Tepas

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961690%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Elizabeth Fox

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961690%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Staci Martin

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961690%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Pamela Wolters

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961690%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Nalini Jayaprakash

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961690%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Alyssa Reddy

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961690%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Bruce Korf

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961690%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Brigitte C Widemann

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961690%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

7 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961690%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

published in

Pediatric Blood & Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961690%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

60

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961690%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961690%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

396-401

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961690%20AND%20SRC:MED&resulttype=core&format=json

Plexiform neurofibromas in NF1: toward biologic-based therapy

12 February 2020

cites work

1 reference

Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts

21 January 2018

1 reference

Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow

21 January 2018

1 reference

Expression of angiogenic factors in neurofibromas

21 January 2018

1 reference

Neurofibroma-associated growth factors activate a distinct signaling network to alter the function of neurofibromin-deficient endothelial cells

21 January 2018

1 reference

Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging

21 January 2018

1 reference

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

21 January 2018

1 reference

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

21 January 2018

1 reference

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

21 January 2018

1 reference

Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

21 January 2018

1 reference

Management of hypertension in angiogenesis inhibitor-treated patients

21 January 2018

1 reference

Mechanisms of hypertension associated with BAY 43-9006.

21 January 2018

1 reference

Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors

21 January 2018

1 reference

Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.

21 January 2018

1 reference

Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate

21 January 2018

1 reference

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

21 January 2018

1 reference

VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation

21 January 2018

1 reference

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

Reporting results of cancer treatment

21 January 2018

1 reference

Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas

21 January 2018

1 reference

Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging

21 January 2018

1 reference

Interobserver reproducibility of volumetric MR imaging measurements of plexiform neurofibromas.

21 January 2018

1 reference

Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images

21 January 2018

1 reference

NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight.

21 January 2018

1 reference

A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors

21 January 2018

1 reference

Automated volumetric growth plate measurement using magnetic resonance imaging for monitoring skeletal toxicity in children treated on investigational drug trials

21 January 2018

1 reference

Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma

21 January 2018

1 reference

Modeling tracer kinetics in dynamic Gd-DTPA MR imaging

21 January 2018

1 reference

Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

21 January 2018

1 reference

PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations

21 January 2018

1 reference

Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.

21 January 2018

1 reference

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

21 January 2018

1 reference

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

21 January 2018

1 reference

Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib

21 January 2018

1 reference

Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment

21 January 2018

1 reference

Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib

21 January 2018

1 reference

Stimulus-evoked release of neuropeptides is enhanced in sensory neurons from mice with a heterozygous mutation of the Nf1 gene

21 January 2018

1 reference

Neurological complications of neurofibromatosis type 1 in adulthood

21 January 2018

1 reference

Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study of 128 cases.

21 January 2018

1 reference

Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations

21 January 2018

1 reference

Loss of NF1 allele in Schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma

21 January 2018

1 reference

12 December 2020

Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas

1 reference

12 December 2020

National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987

1 reference

12 December 2020

Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

1 reference

12 December 2020

Identifiers

DOI

10.1002/PBC.24281

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961690%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961690%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

PubMed publication ID

22961690

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961690%20AND%20SRC:MED&resulttype=core&format=json